The Spectra Optia ® Apheresis System is an automatic blood component separator used to perform various therapeutic apheresis procedures, cell collection and processing procedures. Users could follow all instructions given by the SPO secure and comfortable. However, there are no formal guidelines for the use of specific apheresis devices in therapeutic apheresis. The focus of this review is the application of this Apheresis System in therapeutic apheresis, and its clinical risks and benefits. Although only few data exist evaluating the use of the Spectra Optia Apheresis System, it can be said that the Spectra Optia device is safe to use and comfortable for both the patients and the operators. The therapeutic procedures like therapeutic plasma exchange, procedures with secondary plasma devices, as well as blood cell depletion procedures can be performed efficiently and precisely using this device. Severe adverse events have not been reported. All published data have shown the clinical benefits, which were more pronounced than the clinical risk. The only disadvantage the system has is the use of citrate, especially in plasma-based procedures, as its optimal use has not been evaluated. For the further evaluation of the Spectra Optia Apheresis System, more clinical outcome data are necessary.